PRESENTATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the MASH/NASH field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Presentations
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 3000
No.87
EASL the International Liver CongressTM 2022,
“A nine-strain bacterial consortium improves portal hypertension and insulin signaling and delays non-alcoholic fatty liver disease progression in vivo” MRM Health NV
No.86
AASLD 2021,
“CT-859, A NOVEL FULLY BIASED UNIMOLECULAR DUAL GLP-1 AND GIP RECEPTOR MODULATOR RESOLVES NASH AND FIBROSIS, DECREASES TUMORS, AND IMPROVES SURVIVAL IN A MOUSE NASH MODEL” Carmot Therapeutics
No.85
AASLD 2021,
“ECC0509, A NOVEL PERIPHERALLY DISTRIBUTED AND SELECTIVE SEMICARBAZIDE-SENSITIVE AMINO OXIDASE (SSAO) INHIBITOR FOR NASH TREATMENT” Eccogene
No.84
EASL the International Liver CongressTM 2021,
“First in class, orally active Toll-like receptor signaling inhibitor mosedipimod (PLAG) attenuates molecular, biochemical and histological features of non-alcoholic steatohepatitis (NASH) in vitro and in vivo” Enzychem Lifesciences
No.83
AASLD 2020,
“SELECTIVE ESTROGEN RECEPTOR MODULATOR, OSU-ERB-12, AMELIORATES PRECLINICAL MODELS OF HEPATIC FIBROSIS AND NASH.” Ohio State University
No.82
AASLD 2020,
“PRECLINICAL DEVELOPMENT OF SMALL MOLECULE DRUG DISCOVERY LEADS WITH NOVEL MOAS FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH)” Twoxar
No.81
AASLD 2020,
“IRON LOSS TRIGGERS MITOPHAGY THROUGH INDUCTION OF MITOCHONDRIAL FERRITIN” Kawasaki Medicel School
No.80
EASL the International Liver CongressTM 2020,
“Iron loss-induced mitophagy via mitochondria ferritin suppresses NASH-related hepatocellular carcinoma” Kawasaki Medical School
No.79
EASL the International Liver CongressTM 2020,
“GPNMB modulates hepatic steatogenesis and liver cancer” Heidelberg University
No.78
EASL the International Liver CongressTM 2020,
“2-deoxy-D-glucose encapsulated PLGA nanoparticles suppress hepatocellular carcinoma through cytotoxic effect and activation of antitumor immunity” Kawasaki Medical School
No.77
EASL the International Liver CongressTM 2020,
“Novel autophagy inducer, a4368 improves non-alchoholic steatohepatitis in mice” Autophagy Sciences.
No.76
EASL the International Liver CongressTM 2020,
“Therapeutic efficacy of the chitotriosidase inhibitors in STAM model of non-alcoholic steatohepatitis” OncoArendi Therapeutics SA.
No.75
EASL the International Liver CongressTM 2020,
“A randomized, double-blind, placebo-controlled, first-in-human single ascending dose, multiple ascending dose, and food effect study to evaluate the safety, tolerability, and pharmacokinetic profile of FM101 in healthy volunteers” Future Medicine Co., Ltd.
No.74
DDW 2020,
"NON-ALCOHOLIC STEATOHEPATITIS-ASSOCIATED ALTERATION OF INFLAMMATORY LIPID MEDIATORS, PRIMARY METABOLITES AND MICROBIOME IN A STAM MOUSE MODEL, AND THERAPEUTIC POTENTIAL OF A JAPANESE TRADITIONAL MEDICINE, DAISAIKOTO” TSUMURA & Co.
No.73
DDW 2019,
“Change of Gut Microbiome after Treatment with the Traditional Japanese Medicine Daisaikoto is Associated with Improved Liver Steatosis in a Non-alcoholic Fatty Liver Mouse Model” TSUMURA & Co.
No.72
DDW 2019,
“Influence of the O-GlcNAc Modification in Hepatic Carcinogenesis by Non-alcoholic Fatty Liver Disease” Osaka Medical College
No.71
EASL the International Liver CongressTM 2018,
“LXR inverse agonists reduce steatosis and fibrosis in the STAM™ mouse model but also improve insulin sensitivity in a high fat diet mouse clamp study” Phenex Pharmaceuticals AG
No.70
3rd Annual World Preclinical Congress Europe 2018,
“LXR Inverse Agonists for the Treatment of NASH” Phenex Pharmaceuticals AG
No.69
3rd Annual World Preclinical Congress Europe 2018,
“MTBL0036, a Promising, New Anti-NASH and Antifibrotic Candidate: MTBL0036 showed a decrease in NAFLD Activity score in the STAM™ model” Metabolys, Inc.
No.68
AASLD 2018,
“AXA1125, a Novel Composition of Amino Acids Reprograms the Multifactorial Pathophysiology in NAFLD” Axcella Health Inc.
No.67
AASLD 2018,
“Treatment of Hepatocellular Carcinoma Using 2-Deoxy-D-Glucose Encapsulated in PLGA Nanoparticles in Mice” Kawasaki Medical School
No.66
AASLD 2018,
“Dipeptidyl Peptidase 4 Inhibitors Reduce the Progression of Hepatocellular Carcinoma By Activating T Cell and Natural Killer Cell Chemotaxis in Mice” Kawasaki Medical School
No.65
AASLD 2018,
“Effects of a DPP4 Inhibitor on Progression of Nash-Related Hepatoma and DNA Synthesis Pathway Via p62/Keap1/Nrf2 in a Mouse Model: A Metabolomic Analysis” Kurume University School of Medicine
No.64
AASLD 2018,
“Gemcabene Regulates Hepatic Genes Associated with Inflammation and Fibrosis with Impact on Non-Alcoholic Fatty Liver Disease” Gemphire Therapeutics Inc.
No.63
AASLD 2018,
“CM101, a Novel CCL24 Blocking Antibody, Suppresses Hepatic Injury and Fibrosis In Experimental Models of Nash and Liver Fibrosis” ChemomAb Ltd.
No.62
AASLD 2018,
“Unexpected Antidiabetic Effects Combined with Antifibrotic Activities of LXR Inverse Agonists in Mouse Models of NAFLD/Nash” Phenex Pharmaceuticals AG
No.61
The 78th Scientific Sessions ADA, 2018,
“Canagliflozin, an SGLT2 Inhibitor, Prevents Development of Hepatocellular Carcinoma (HCC) from Nonalcoholic Steatohepatitis (NASH) in a Mouse Model of NASH-HCC Under Diabetic State” Dokkyo Medical University
No.60
The 78th Scientific Sessions ADA, 2018,
“Combination of SGLT2 Inhibitor and Novel Selective PPARα Modulator, Tofogliflozin (Tofo) and Pemafibrate (Pema), Improves Survival Rate in STAM™ Mice as a Diabetic NASH Model” Kowa Company Ltd.
No.59
EASL the International Liver CongressTM 2018,
“Interfering with local fibrotic platelet activation significantly inhibits fibrosis in multiple animal models: suggestions of the importance of the platelet-wound healing axis for fibrosis” Symic Bio, Inc.
No.58
EASL the International Liver CongressTM 2018,
“BMS-986036, a PEGylated fibroblast growth factor 21 analogue, reduces fibrosis and PRO-C3 in a mouse model of non-alcoholic steatohepatitis” Bristol-Myers Squibb Company
No.57
EASL the International Liver CongressTM 2018,
“LJN452 (tropifexor) attenuates steatohepatitis, inflammation, and fibrosis in dietary mouse models of nonalcoholic steatohepatitis” Genomics Institute of the Novartis Research Foundation
No.56
EASL the International Liver CongressTM 2018,
“Clinical-grade human liver mesenchymal stem cells reduce NAS score and fibrosis progression in advanced stage NASH pre-clinical model through immunomodulation” Promethera Biosciences LLC
No.55
First EASL NAFLD Summit 2017,
“Dual CCR2/5 antagonist decreases hepatic inflammation in acute liver injury and NASH metabolic animal models” Pfizer Inc.
No.54
First EASL NAFLD Summit 2017,
“AXA1125, a novel defined amino acid composition (DAAC), improves NAFLD activity score (NAS) and reduces fibrosis in two rodent models of nonalcoholic steathepatitis (NASH)” Axcella Health, Inc.
No.53
AASLD 2017,
“The Anti-Fibrogenic and Liver Protective Effects of Namodenoson (CF102) in a Non-Alcoholic Steatohepatitis Model” Can-Fite BioPharma Ltd.
No.52
AASLD 2017,
“DPP4 Inhibitor Suppressed Progression of NASH-related Hepatocellular Carcinoma with Inhibition of Metabolic Reprograming in p62-Keap 1-Nrf2-pentose Phosphate Pathway in a Mouse Model: A Metabolomic Analysis” Kurume University School of Medicine
No.51
AASLD 2017,
“CB4209 and CB4211 Reduce the NAFLD Activity Score in the STAM™ Model of NASH, Reduce Triglyceride Levels, and Induce Selective Fat Mass Loss in DIO Mice” CohBar, Inc.
No.50
AASLD 2017,
“Combination Treatment of LJN452 and Cenicriviroc Snows Additive Effects in a Diet-Induced NASH Model” Genomics Institute of the Novartis Research Foundation/Allergan plc/Novartis Institutes for BioMedical Research, Inc.
No.49
AASLD 2017,
“Gemcabene Attenuates the NAFLD Activity and Fibrosis Scores, and Downregulates Hepatic Inflammatory Genes in the STAM™ Murine Model of NASH-HCC” Gemphire Therapeutics Inc.
No.48
DDW 2017,
“A HMG-CoA Reductase Inhibitor, Rosuvastatin, as a Potential Preventive Drug for The Development of Hepatocellular Carcinoma Associated With Non-alcoholic Fatty Liver Disease in Mice” Osaka Medical College
No.47
EASL the International Liver CongressTM 2017,
“Anti-fibrotic effect of NV556,a sanglifehrin-based cyclophilin inhibitor,in a preclinical model of non-alcoholic steatohepatitis” Neuro Vive Pharmaceutical AB
No.46
AACR 2017,
“Inhibition of gene expression during non-alcoholic steatohepatitis (NASH)-related hepatocarcinogenesis is mediated by histone H4 lysine 16 deacetylation” FDA-National Center for Toxicological Research.
No.45
AACR 2017,
“Alterations in the chromatin accessibility in nonalcoholic steatohepatitis-associated hepatocellular carcinoma” FDA-National Center for Toxicological Research
No.44
AACR 2017,
“Role of miRNAome deregulation in the pathogenesis of non-alcoholic steatohepatitis (NASH)-derived hepatocellular carcinoma” FDA-National Center for Toxicological Research
No.43
AASLD 2017,
Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease, “The Novel Antidiabetic Candidate MTBL0036 Greatly Diminishes The NAFLD Activity Score in The STAM™ Mouse Model of NASH” Metabolys Inc.
No.42
AASLD 2017,
Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease, “DUR-928, An Endogenous Regulatory Molecule, Exhibits Anti-Inflammatory and Antifibrotic Activity in a Mouse Model of NASH” DURECT Corporation
No.41
AASLD 2016,
“A Phase 2 study of BMS-986036 (Pegylated FGF21) in Obese Adults with Type 2 Diabetes and a High Prevalence of Fatty Liver” Bristol-Myers Squibb Company
No.40
AASLD 2016,
“Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis” Bristol-Myers Squibb Company.
No.39
DDW 2016,
“Inhibition of the Ileal Bile Acid Transporter (IBAT) by A4250 Reduces Hepatic Damage in a Mouse Model of Non-Alcoholic Steatohepatitis (NASH)”Albireo AB
No.38
EASL the International Liver CongressTM 2016,
“DPP4 Inhibitor Suppresses Steatohepatitis and HCC Progression with Glucose Re-Programing in a Mouse Model of NASH” Kurume University School of Medicine
No.37
HEP DART 2015,
“The Cyclophilin Inhibitor, CPI-431-32, is a Hepatitis B Oral Drug Candidate with Antiviral and Antifibrotic Activities” Ciclofilin Pharmaceuticals Inc.
No.36
WDC 2015,
“Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes” Dokkyo Medical University
No.35
AASLD 2015,
“Anti-Fibrotic Effect of Autotaxin and LPA1R Antagonists in a Rodent Model of NASH” Bristol-Myers Squibb Company
No.34
AASLD 2015,
“Sitagliptin, a Dipeptidyl Peptidase 4 inhibitor, Suppressed Tumor Progression with Down-regulation of Nrf Nuclear Expression in a Mouse Model of Non-alcoholic Steatohepatitis-related Hepatocellular Carcinoma” Kurume University School of Medicine
No.33
AASLD 2015,
“Reduction of Hepatic 27-Hydroxycholesterol in Steatohepatitis Model Mice with Insulin Resistance” Tokyo Medical University Ibaraki Medical Center
No.32
AASLD 2015,
“Disturbance of regulatory T cells, MDSCs and NK cells is involved in NASH and mouse model of NASH” Tohoku University Hospital.
No.31
AASLD 2015,
“Mechanism of Action of the Anti-NASH effects of Solithromycin in a Predictive NASH HCC Mouse Model” Cempra Pharmaceuticals, Inc.
No.30
DDW 2015,
“Effects of Sitagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Tumor Progression and p62/SQSTM1 Subcellular Localization in a Mouse Model of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma” Kurume University
No.29
Keystone Symposia 2015,
DGAT2 Inhibition Prevents NAFLD and Fibrosis in the STAM™ Mouse Model of NASH“ Pfizer Inc.
No.28
Keystone Symposia 2015,
“Oxidized-Phospholipid Small Molecule Inhibits Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis“ Vascular Biogenics Ltd
No.27
AASLD 2014,
“L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway“ Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
No.26
AASLD 2014,
“MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model“ MediciNova, Inc.
No.25
ICLAF 2014,
“MN-001 (tipelukast), a nonselective phosphodiesterase, 5-lipoxygenase, leukotriene, phospholipase C and thromboxane A2 inhibitor, demonstrates anti-fibrotic effects in the bleomycin-induced idiopathic pulmonary fibrosis mouse model“ MediciNova, Inc.
No.24
ADA 2014,
“Liraglutide prevents steatohepatitis, liver fibrosis, and accompanying carcinogenesis in a diabetes and nonalcoholic steatohepatitis mouse model treated with STZ-HFD“ Saga University
No.23
ATS 2014,
“Solithromycin Reduces Inflammation In Mice Caused By Bleomycin-Induced Lung Injury“ Cempra, Inc.
No.21
AACR 2014,
“Clinicopathological characterization of non-alcoholic Steatohepatitis (NASH)-derived Hepatocellular carcinoma (HCC) as a patient stratification model in mice)” The Jikei University School of Medicine
No.20
Keystone Symposia 2014,
“The NADPH Oxidase (NOX) Inhibitor GKT137831 Alleviates Liver Inflammation and Fibrosis in a Mouse Model of Non-Alcoholic Steatohepatitis (NASH)” Genkyotex S.A.
No.19
15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV,
“Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH” Tobira Therapeutics Inc.
No.18
AASLD 2013,
“Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH” Tobira Therapeutics Inc.
No.17
AASLD 2013,
“L-carnitine prevents progression of non-alcoholic steatohepatitis with regulation of mitochondrial β-oxidation and redox system in NASH model Mice” Okayama University
No.16
FASEB SRC 2013, Lysophospholipid and Other Related Mediators – From Bench to Clinic,
“ATX inhibition prevents progression of non-alcoholic steatohepatitis (NASH) in a hypoinsulinemic mouse model of progressive liver disease” F. Hoffmann-La Roche, Ltd
No.15
DDW 2013,
“Vitamin E and L-Carnitine Prevents Progression of Non-Alcoholic Steatohepatitis With Regulation of Intestinal Inflammasome Activation in NASH Model Mice” Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
No.14
DDW 2013,
“Rosuvastatin Prevents Liver Tumorigenesis in High-Fat Diet-Fed Mice“ 2nd Department of Internal Medicine Osaka Medical College
No.13
AASLD 2012,
“Comparative proteomic analysis of the liver in a murine model of non- alcoholic steatohepatitis” Third Department of Internal Medicine, Niigata University Medical School
No.12
AASLD 2012,
“Inhibition of endoplasmic reticulum stress by 4-phenylbutyrate prevents steatohepatitis progression and tumorigenesis in NASH-HCC model mice” Department of Gastroenterology, Juntendo University School of Medicine
No.11
AASLD 2012,
“Galectin-3 targeting drugs inhibit multiple pathological pathways leading to improvement of non-alcoholic steatohepatitis (NASH)” Galectin Therapeutics Inc.
No.10
Cancer Science,
AASLD 2012, “Hepatic gene expression of the SPTLC3 subunit of serine palmitoyltransferase is associated with the development of liver cancer in a NASH mouse model” Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medicine and Dental Sciencesq
No.9
The 72th Scientific Sessions ADA,
2012, “Linagliptin is an Effective Therapeutic for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)” Boehringer Ingelheim GmbH & Co. KG
No.8
DDW 2012,
“A Novel Murine Model Recapitulates the Pathogenesis of Human Non-alcoholic steatohepatitis (NASH) and NASH-related Hepatocellular Carcinoma”
No.7
DDW 2012,
“Effects of Telmisartan on a Murine Model of Non-alcoholic Steatohepatitis (NASH) and NASH-related Hepatocellular Carcinoma”
No.6
DDW 2012,
“The Chemical Chaperon 4-Phenylbutyrate Inhibits Liver Fibrosis and Tumorigenesis in High-Fat Diet With N-acetyl-β-D-glucosaminedase Inhibitor-Induced NASH Model Mice”Department of Gastroenterology, Juntendo University School of Medicine
No.5
EASL The International Liver CongressTM 2012 – 47th Annual Meeting of the European Association for the Study of the Liver,
“FXR agonists prevent steatosis, hepatocyte death and progression of NASH towards HCC in a hypoinsulinaemic mouse model of progressive liver disease” Phenex Pharmaceuticals AG
No.4
AASLD 2011,
“The Dipeptidyl Peptidase-4 Inhibitor Linagliptin is an Effective Therapeutic for Metabolic Liver Disease in Several Rodent Models of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)” Boehringer Ingelheim GmbH & Co. KG
No.3
EASL Special Conference – Liver Transplantation 2011,
“Improvement of steatosis, inflammation, and fibrosis in a mouse model of steatohepatitis following treatment with galectin inhibitor” Galectin Therapeutics Inc.
No.2
EASL The International Liver CongressTM 2011 – 46th Annual Meeting of the European Association for the Study of the Liver,
Novel FXR agonists with potent lipid lowering, insulin sensitising, anti-inflammatory and anti-fibrotisation effects in mouse models of metabolic syndrome and NASH” Phenex Pharmaceuticals AG
No.1
The 9th JSH SingleTopic Conference “NASH 2010”,
Strong Anti-steatotic and Anti-fibrotic Effects of Novel FXR Agonists in a Murine NASH Model that Resembles Human NASH” Phenex Pharmaceuticals AG
testtesttest
testtesttest